China NMPA
China’s CANbridge Reports Positive Phase 1 Data of Contender to AstraZeneca’s Complement Inhibitor
2022-02-08
Antengene’s XPO1 Inhibitor Receives First-In-Class Approval in China for Multiple Myeloma
2021-12-20